Rifaat Safadi, EASL ILC 2021: Impact of Liver Disease on SARS-CoV-2 Vaccine Response
It was a pleasure to speak with Prof. Rifaat Safadi (Hadassah University Hospital, Ein Kerem, Jerusalem) about the impact of advanced chronic liver disease on the efficacy of the Pfizer and Moderna mRNA SARS-CoV-2 vaccines.
His abstract entitled ‘Elderly with advanced liver fibrosis had lower response to Pfizer’s SARS-CoV-2 vaccine response’ was presented at EASL ILC 2021, 23-26 June.
Questions
- Could you tell us a little about the rationale for investigating the impact of Pfizer’s and Moderna’s mRNA SARS-CoV-2 vaccines on those with advanced chronic liver disease? (0:15)
- Could you tell us a little about the study you conducted to investigate this? (0:36)
- What were your overall findings? (2:56)
- In your opinion, what do these results suggest and how could they impact clinical decisions? (5:03)
Disclosures: Prof. Rifaat Safadi has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
